Celgene – Hot or Not

PUBLISHED: Thu, 29 Jun 2017 05:36:57 GMT
Share


Celgene is a biopharmaceutical company focused on cancer and inflammatory diseases. It has commercial-stage products and a significant research pipeline. It has a market cap of $101.8 billion, a price to earnings ratio of 49.29. Guest Lungile Malinga from Effectus Capital and resident expert Paul Theron from Vestact decide whether is Celgene hot or not

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.